Search Results
10
Everything
Search Filters
Organization
Anthos Therapeutics
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk
March 29, 2025 15:30 ET
|
Anthos Therapeutics
--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared to rivaroxaban (Xarelto) was even greater in patients ≥75...
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atrial Fibrillation
January 22, 2025 17:00 ET
|
Anthos Therapeutics
Secondary endpoints also showed a highly significant 67% reduction in major bleeding and an 89% reduction in gastrointestinal (GI) bleeding The company’s AZALEA-TIMI 71 study is the longest...
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET
|
Anthos Therapeutics
Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy taking abelacimab as compared to rivaroxaban AZALEA-TIMI 71...
Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer
October 31, 2024 08:00 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...
Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer
October 10, 2024 08:00 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke
June 06, 2024 08:15 ET
|
Anthos Therapeutics
75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
April 22, 2024 11:09 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by...
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
June 26, 2023 07:00 ET
|
Anthos Therapeutics
Patient-Centric Survey Conducted in Collaborationwith StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology,...
Les autorités réglementaires chinoises et japonaises approuvent les essais cliniques sur l'abelacimab, un inhibiteur du facteur XI/XIa à double action d'Anthos Therapeutics
June 09, 2023 06:18 ET
|
Anthos Therapeutics
Moins de 26 % des patients chinois souffrant de fibrillation auriculaire se voient prescrire un anticoagulant, tandis qu'au Japon, près d'un tiers des patients sont insuffisamment traités Environ...
Zulassungsbehörden in China und Japan genehmigen klinische Studien für doppelt wirkenden Faktor XI/XIa-Inhibitor Abelacimab von Anthos Therapeutics
June 09, 2023 06:18 ET
|
Anthos Therapeutics
Weniger als 26 % der chinesischen Patienten mit Vorhofflimmern bekommen einen Gerinnungshemmer verschrieben, während in Japan fast ein Drittel der Patienten unterbehandelt wird Ungefähr 63 % der...